Your browser is no longer supported. Please, upgrade your browser.
OCGN Ocugen, Inc. daily Stock Chart
Ocugen, Inc.
Index- P/E- EPS (ttm)-3.50 Insider Own0.10% Shs Outstand135.01M Perf Week3.57%
Market Cap44.37M Forward P/E- EPS next Y-0.11 Insider Trans136.91% Shs Float121.38M Perf Month-28.77%
Income-30.50M PEG- EPS next Q-0.02 Inst Own7.40% Short Float4.08% Perf Quarter46.68%
Sales0.04M P/S1041.10 EPS this Y89.60% Inst Trans316.88% Short Ratio0.15 Perf Half Y18.80%
Book/sh0.18 P/B1.90 EPS next Y60.70% ROA-159.50% Target Price- Perf Year-97.41%
Cash/sh0.12 P/C2.96 EPS next 5Y- ROE-614.70% 52W Range0.17 - 16.80 Perf YTD-34.25%
Dividend- P/FCF- EPS past 5Y50.60% ROI- 52W High-98.01% Beta2.46
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low96.94% ATR0.04
Employees16 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)45.57 Volatility10.65% 11.92%
OptionableNo Debt/Eq0.42 EPS Q/Q88.00% Profit Margin- Rel Volume0.29 Prev Close0.34
ShortableYes LT Debt/Eq0.14 EarningsAug 14 BMO Payout- Avg Volume34.03M Price0.33
Recom2.50 SMA20-6.36% SMA50-19.71% SMA200-15.63% Volume1,482,883 Change-2.08%
Sep-16-20 07:30AM  
Sep-11-20 01:50PM  
Sep-09-20 02:48PM  
Sep-08-20 04:25PM  
Sep-03-20 12:51PM  
Aug-28-20 01:42PM  
Aug-21-20 03:02PM  
Aug-14-20 07:30AM  
Aug-10-20 11:52AM  
Aug-07-20 01:08PM  
Aug-06-20 01:45PM  
Jul-27-20 07:30AM  
Jul-21-20 05:15PM  
Jun-12-20 01:39PM  
Jun-03-20 08:30AM  
Jun-01-20 09:20AM  
May-08-20 07:30AM  
Apr-22-20 09:39AM  
Apr-07-20 08:01AM  
Mar-27-20 07:30AM  
Mar-20-20 07:30AM  
Mar-03-20 07:30AM  
Feb-10-20 07:30AM  
Jan-03-20 02:44PM  
Dec-09-19 09:29AM  
Nov-08-19 07:30AM  
Nov-06-19 09:01AM  
Nov-04-19 07:30AM  
Oct-25-19 07:30AM  
Oct-23-19 08:30AM  
Oct-09-19 07:30AM  
Oct-07-19 07:00AM  
Oct-01-19 07:30AM  
Sep-30-19 04:05PM  
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Castillo KirstenDirectorMay 28Buy0.3175,00023,49875,000May 29 06:48 PM
Musunuri ShankarChief Executive OfficerDec 12Buy0.35143,00050,050406,000Dec 13 08:44 PM
Musunuri ShankarChief Executive OfficerDec 11Buy0.41263,000107,830263,000Dec 13 08:44 PM
Zhang JungeDirectorDec 04Buy0.44220,00096,800818,578Dec 05 02:01 PM
Zhang JungeDirectorNov 27Buy0.37270,00099,900600,078Dec 02 07:37 AM
Zhang JungeDirectorNov 25Buy0.27115,00031,050330,078Nov 26 07:18 PM
Zhang JungeDirectorNov 22Buy0.2880,00022,400215,078Nov 26 07:18 PM
Subramanian SanjayChief Financial OfficerNov 22Buy0.285,0001,40010,000Nov 26 07:17 PM
Zhang JungeDirectorNov 18Buy0.41100,00041,000135,078Nov 20 06:31 PM